{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T13:41:11Z","timestamp":1768484471670,"version":"3.49.0"},"reference-count":0,"publisher":"Canadian Society of Healthcare-Systems Pharmacy","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CJHP"],"abstract":"<jats:p>Background: In select clinical scenarios, IV administration of iron is suitable for management of iron deficiency anemia; however, for most patients, oral administration of iron is the mainstay of treatment. At the Red Deer Regional Hospital Centre, in Red Deer, Alberta, high utilization of IV iron has resulted in limited access to this medication for the treatment of ambulatory patients, as well as significant usage of health care resources. \nObjectives: The primary objective was to compare patient characteristics, specifically pretreatment laboratory test results and previous use of oral iron, among those receiving IV iron therapy in an ambulatory setting before and after implementation of an iron sucrose order set. For secondary objectives, the aforementioned groups were compared with regard to meeting the diagnostic criteria for iron deficiency anemia, with or without pretreatment oral iron or blood transfusion, and the dosing characteristics for IV iron.\nMethods: A retrospective electronic chart review was performed for ambulatory patients who received IV iron between January 1, 2020, and January 31, 2022.\nResults: A total of 436 unique treatment courses were included in the analysis. The following pretreatment laboratory results were observed before and after implementation of the iron sucrose order set: mean hemoglobin 105.8 (standard deviation [SD] 21.9) g\/L versus 102.2 (SD 18.5) g\/L; mean of mean corpuscular volume (MCV) 82.2 (SD 9.4) fL versus 79.2 (SD 8.9) fL; and median ferritin 7 (interquartile range [IQR] 4\u201312) \u00b5g\/L versus 6 (IQR 4\u201311) \u00b5g\/L. Only the difference in MCV values was statistically significant (p = 0.001). \nConclusions: The implementation of an iron sucrose order set for ambulatory patients did not have a significant effect on pretreatment laboratory parameters among patients for whom IV iron was prescribed. Further stewardship initiatives could be beneficial in improving the appropriateness of IV iron use.\nR\u00c9SUM\u00c9\nContexte\u00a0: Dans certains sc\u00e9narios cliniques, l\u2019administration de fer par voie intraveineuse (IV) convient \u00e0 la prise en charge de l\u2019an\u00e9mie ferriprive; cependant, pour la plupart des patients, l\u2019administration de fer par voie orale constitue le pilier du traitement. Au centre hospitalier r\u00e9gional Red Deer, \u00e0 Red Deer, en Alberta, l\u2019utilisation \u00e9lev\u00e9e du fer\u00a0par IV a entra\u00een\u00e9 un acc\u00e8s limit\u00e9 \u00e0 ce m\u00e9dicament pour le traitement des patients ambulatoires, ainsi qu\u2019une utilisation importante des ressources de sant\u00e9.\nObjectifs : L\u2019objectif principal consistait \u00e0 comparer les caract\u00e9ristiques des patients, en particulier les r\u00e9sultats de tests de laboratoire avant traitement et l\u2019utilisation ant\u00e9rieure de fer par voie orale, chez ceux recevant un traitement de fer par IV en milieu ambulatoire avant et apr\u00e8s la mise en \u0153uvre d\u2019un protocole de prescription de fer sucros\u00e9. Les objectifs secondaires, quant \u00e0 eux, \u00e9taient la comparaison des groupes susmentionn\u00e9s en ce qui concerne la satisfaction des crit\u00e8res diagnostiques de l\u2019an\u00e9mie ferriprive, avec ou sans pr\u00e9traitement de fer administr\u00e9 par voie orale ou par transfusion sanguine, ainsi que les caract\u00e9ristiques posologiques du fer administr\u00e9 par IV.\nM\u00e9thodes : Un examen r\u00e9trospectif des dossiers \u00e9lectroniques a \u00e9t\u00e9 r\u00e9alis\u00e9 pour les patients ambulatoires ayant re\u00e7u du fer par IV entre le 1er janvier 2020 et le 31 janvier 2022.\nR\u00e9sultats : Au total, 436 traitements uniques ont \u00e9t\u00e9 inclus dans l\u2019analyse. Les r\u00e9sultats suivants de tests de laboratoire avant traitement ont \u00e9t\u00e9 observ\u00e9s avant et apr\u00e8s la mise en \u0153uvre du protocole de prescription de fer sucros\u00e9 : h\u00e9moglobine moyenne 105,8 g\/L (\u00e9cart type [\u00c9T] 21,9) contre 102,2 g\/L (\u00c9T 18,5); moyenne du volume corpusculaire moyen (VCM) 82,2 fL (\u00c9T 9,4) contre 79,2 fL (\u00c9T 8,9); et ferritine m\u00e9diane 7 \u03bcg\/L (intervalle interquartile [IIQ] 4\u201312) contre 6 \u03bcg\/L (IQR 4\u201311). La seule diff\u00e9rence statistiquement significative concernait les valeurs VCM (p = 0,001). \nConclusions\u00a0: La mise en \u0153uvre d\u2019un protocole de prescription de fer sucros\u00e9 pour les patients ambulatoires n\u2019a pas eu d\u2019effet significatif sur les param\u00e8tres biologiques avant traitement chez les patients pour lesquels du fer par IV a \u00e9t\u00e9 prescrit. D\u2019autres initiatives de gestion pourraient \u00eatre b\u00e9n\u00e9fiques pour am\u00e9liorer la pertinence de l\u2019utilisation du fer\u00a0IV.<\/jats:p>","DOI":"10.4212\/cjhp.3500","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T17:42:21Z","timestamp":1704476541000},"source":"Crossref","is-referenced-by-count":1,"title":["Describing and Comparing Patient Factors Associated with Use of Parenteral Iron before and after Implementation of an Order Set for Parenteral Iron (DECODE IRON)"],"prefix":"10.4212","volume":"77","author":[{"given":"Cameron","family":"Black","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Brownlee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darren","family":"Pasay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2732","published-online":{"date-parts":[[2024,1,10]]},"container-title":["Canadian Journal of Hospital Pharmacy"],"original-title":[],"link":[{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3500\/5139","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3500\/5158","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/download\/3500\/5139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,12]],"date-time":"2024-01-12T18:10:58Z","timestamp":1705083058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cjhp-online.ca\/index.php\/cjhp\/article\/view\/3500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,10]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,10]]}},"URL":"https:\/\/doi.org\/10.4212\/cjhp.3500","relation":{},"ISSN":["1920-2903","0008-4123"],"issn-type":[{"value":"1920-2903","type":"electronic"},{"value":"0008-4123","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1,10]]},"article-number":"e3500"}}